Oasmia presses ahead with new water-soluble paclitaxel formulation
This article was originally published in Scrip
Executive Summary
The US FDA has granted orphan drug designation for Oasmia Pharmaceutical's Paclical (paclitaxel) for the treatment of ovarian cancer. The Swedish company hopes to achieve a 35% market share, its CEO, Julian Aleksov, told Scrip.